ArticleScientific reports2020

Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer.

E Sun Paik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.